203 related articles for article (PubMed ID: 26520416)
1. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic role of BAP1 in serous effusions.
Davidson B; Tötsch M; Wohlschlaeger J; Hager T; Pinamonti M
Hum Pathol; 2018 Sep; 79():122-126. PubMed ID: 29802871
[TBL] [Abstract][Full Text] [Related]
3. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Davidson B
Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
[TBL] [Abstract][Full Text] [Related]
4. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
5. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
6. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
7. Lamellar Inclusions within Hyperplastic Endoplasmic Reticulum in Benign Mesothelial Cells.
Haefliger S; Jain D; Menter T; Vlajnic T; Savic Prince S; Hopfer H; Mihatsch MJ; Bubendorf L
Acta Cytol; 2020; 64(6):572-576. PubMed ID: 32599592
[TBL] [Abstract][Full Text] [Related]
8. Soluble AXL is ubiquitously present in malignant serous effusions.
Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
[TBL] [Abstract][Full Text] [Related]
9. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
10. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
11. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
12. Significance of flower pot cells in effusion cytology.
Bharani V; Singh P; Gupta N; Srinivasan R
Diagn Cytopathol; 2017 Oct; 45(10):925-927. PubMed ID: 28560851
[TBL] [Abstract][Full Text] [Related]
13. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
[TBL] [Abstract][Full Text] [Related]
14. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
[TBL] [Abstract][Full Text] [Related]
15. p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology.
Mayall F; Heryet A; Manga D; Kriegeskotten A
Cytopathology; 1997 Feb; 8(1):9-12. PubMed ID: 9068950
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic role of PTEN and ARID1A in serous effusions.
Davidson B; Pinamonti M; Cuevas D; Holth A; Zeppa P; Hager T; Wohlschlaeger J; Tötsch M
Virchows Arch; 2018 Mar; 472(3):425-432. PubMed ID: 29170871
[TBL] [Abstract][Full Text] [Related]
17. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
Chapel DB; Husain AN; Krausz T; McGregor SM
Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
[TBL] [Abstract][Full Text] [Related]
18. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
Maguire B; Whitaker D; Carrello S; Spagnolo D
Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591
[TBL] [Abstract][Full Text] [Related]
20. Tenascin-X is a novel diagnostic marker of malignant mesothelioma.
Yuan Y; Nymoen DA; Stavnes HT; Rosnes AK; Bjørang O; Wu C; Nesland JM; Davidson B
Am J Surg Pathol; 2009 Nov; 33(11):1673-82. PubMed ID: 19738457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
